@article{Wollenberg_Marcoux_Silverberg_Aoki_Baselga_Zhang_Levit_Taieb_Rossi_2022, title={Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis}, volume={102}, url={https://medicaljournalssweden.se/actadv/article/view/854}, DOI={10.2340/actadv.v102.854}, abstractNote={<p class="p1">This <em>post hoc</em> analysis examined SCORing Atopic Dermatitis (SCORAD) outcomes in 471 paediatric patients (children age 6–<12 years, <em>n </em>= 304; adolescents age 12–<18 years, <em>n </em>= 167) with atopic dermatitis treated with dupilumab, <span class="s1">±</span> topical corticosteroids, in two 16-week phase 3 randomized controlled trials and a 1-year interim data cut of a subsequent open-label extension study. Paediatric patients treated with dupilumab (<span class="s1">±</span> topical corticosteroids) had significantly lower SCORAD, objective SCORAD (o-SCORAD), and individual SCORAD components from week 3 to 16 compared with placebo (<span class="s1">±</span> topical corticosteroids) in the randomized controlled trials. The results were sustained or continuously improved over 1 year of open-label treatment with dupilumab <span class="s1">±</span> topical corticosteroids. SCORAD-50 was achieved in almost all patients (91.3–91.8%) by week 52 with continued dupilumab treatment across age groups. Almost all (>  86%) patients achieved mild or absent pruritus and sleep loss at week 52. In conclusion, dupilumab <span class="s1">±</span> topical corticosteroids resulted in rapid and significant improvements in all aspects of SCORAD analysed, and the results were sustained over 1 year.</p>}, journal={Acta Dermato-Venereologica}, author={Wollenberg, Andreas and Marcoux, Danielle and Silverberg, Jonathan I. and Aoki, Valeria and Baselga, Eulalia and Zhang, Haixin and Levit, Noah A. and Taieb, Alain and Rossi, Ana B.}, year={2022}, month={May}, pages={adv00726} }